Jeroen van Beek
Net worth: 196 062 $ as of 2024-03-30
Profile
Jeroen van Beek worked as a Marketing Director at Pfizer Inc. from 1999 to 2007.
He then worked as VP-Global Commercial Operations & Development at Alexion Pharmaceuticals, Inc. from 2007 to 2017.
In 2018, he briefly worked as Chief Commercial Officer & Senior Vice President at Tricida, Inc. From 2019 to 2022, he worked as Chief Commercial Officer & Executive VP at AlloVir, Inc. Dr. van Beek received his undergraduate degree from the University of Virginia, his doctorate from Cornell University, and his MBA from the University of Virginia Darden School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ALLOVIR INC
0.23% | 2023-03-09 | 259,685 ( 0.23% ) | 196 062 $ | 2024-03-30 |
Former positions of Jeroen van Beek
| Companies | Position | End |
|---|---|---|
| ALLOVIR, INC. | Corporate Officer/Principal | 2022-11-22 |
| TRICIDA, INC. | Corporate Officer/Principal | 2018-08-30 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2016-12-31 |
| PFIZER, INC. | Sales & Marketing | 2006-12-31 |
Training of Jeroen van Beek
| University of Virginia | Undergraduate Degree |
| Cornell University | Doctorate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| TRICIDA, INC. | Health Technology |
| ALLOVIR, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Jeroen van Beek
